Article Information
History
- January 5, 2024.
Article Versions
- Version 1 (September 26, 2023 - 18:49).
- Version 2 (September 27, 2023 - 11:14).
- Version 3 (November 26, 2023 - 05:55).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sébastien Benzekry1,✉,
- Mélanie Karlsen1,
- Célestin Bigarré1,
- Abdessamad El Kaoutari1,
- Bruno Gomes2,
- Martin Stern3,
- Ales Neubert4,
- Rene Bruno5,
- François Mercier6,
- Suresh Vatakuti7,
- Peter Curle8 and
- Candice Jamois9
- 1COMPutational pharmacology and clinical Oncology Department, Inria Sophia Antipolis–Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France
- 2Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Switzerland
- 3Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Zurich, Switzerland
- 4Pharma Research and Early Development, Data & Analytics, Roche Innovation Center Basel, Switzerland
- 5Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Marseille France
- 6Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Roche Innovation Center Basel
- 7Pharma Research and Early Development, Predictive Modeling and Data Analytics, Roche Innovation Center Basel, Switzerland
- 8Inovigate, Basel, Switzerland
- 9Pharma Research and Early Development, Translational PKPD and Clinical Pharmacology, Roche Innovation Center Basel, Switzerland
- ↵✉For correspondence:
sebastien.benzekry{at}inria.fr
Posted January 05, 2024.
Predicting survival and trial outcome in non-small cell lung cancer integrating tumor and blood markers kinetics with machine learning
